FDA Drug Safety Podcasts: Resources for drug information

被引:2
|
作者
Wu, Kimberly [1 ,2 ,3 ]
Shepherd, Jennifer [4 ,5 ]
Jackson, Steven [5 ]
Chew, Catherine [4 ,5 ]
机构
[1] Purdue Univ, Coll Pharm, Indianapolis, IN USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] US FDA, Silver Spring, MD 20993 USA
[4] US PHS, Silver Spring, MD USA
[5] US FDA, Div Drug Informat, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
关键词
Podcasts; drug safety; drug information; Food and Drug Administration; social media; SOCIAL MEDIA;
D O I
10.1331/JAPhA.2013.12120
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To describe a Web-based drug information service provided by the Food and Drug Administration (FDA) to increase the reach of Drug Safety Communications to pharmacists and other health professionals. Setting: The Division of Drug Information (DDI) within the FDA Center for Drug Evaluation and Research (CDER), Office of Communications, Silver Spring, MD, between January 2010 and April 2012. Practice description: DDI provides drug information services regarding human drug products and expert advice and guidance on all aspects of CDER activities. Customers include consumers, health professionals, regulated industry, insurance companies, academia, law enforcement, and other government agencies (national and international). Practice innovation: Use of audio podcasts to disseminate timely drug safety information targeted toward pharmacists and other health professionals. Results: Since 2010, DDI has recorded and published 119 FDA Drug Safety Podcasts that have reached more than 620,000 individuals. Conclusion: FDA Drug Safety Podcasts serve as portable and convenient options for pharmacists to stay current on the latest drug safety information. Pharmacists are encouraged to explore incorporating Web-based technologies, such as audio podcasts, into their practices.
引用
收藏
页码:188 / 192
页数:5
相关论文
共 50 条
  • [2] DRUG SAFETY AND FDA
    PISANI, JM
    [J]. FOOD DRUG COSMETIC LAW JOURNAL, 1966, 21 (02): : 68 - 77
  • [3] FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science
    Fang, Hong
    Harris, Stephen C.
    Liu, Zhichao
    Zhou, Guangxu
    Zhang, Guoping
    Xu, Joshua
    Rosario, Lilliam
    Howard, Paul C.
    Tong, Weida
    [J]. DRUG DISCOVERY TODAY, 2016, 21 (10) : 1566 - 1570
  • [4] FDA and Postapproval Drug Safety
    不详
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (06) : 25N - 25N
  • [5] Neonatal Safety Information Reported to the FDA During Drug Development Studies
    Avant, Debbie
    Baer, Gerri
    Moore, Jason
    Zheng, Panli
    Sorbello, Alfred
    Ariagno, Ron
    Yao, Lynne
    Burckart, Gilbert J.
    Wang, Jian
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (01) : 100 - 108
  • [6] Neonatal Safety Information Reported to the FDA During Drug Development Studies
    Debbie Avant
    Gerri Baer
    Jason Moore
    Panli Zheng
    Alfred Sorbello
    Ron Ariagno
    Lynne Yao
    Gilbert J. Burckart
    Jian Wang
    [J]. Therapeutic Innovation & Regulatory Science, 2018, 52 : 100 - 108
  • [7] Coverage of FDA Medication Boxed Warnings in Commonly Used Drug Information Resources
    Cheng, Christine M.
    Guglielmo, B. Joseph
    Maselli, Judy
    Auerbach, Andrew D.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (09) : 831 - 833
  • [8] FDA information systems, Sentinel Initiative seek more timely drug safety information
    Wechsler, Jill
    [J]. FORMULARY, 2010, 45 (04) : 136 - 137
  • [9] FDA criticized on drug safety monitoring
    Hileman, B
    [J]. CHEMICAL & ENGINEERING NEWS, 2006, 84 (18) : 7 - 7
  • [10] FDA creates panel on drug safety
    Hanson, D
    [J]. CHEMICAL & ENGINEERING NEWS, 2005, 83 (08) : 10 - 10